Checkmate Pharmaceuticals, Inc.
Save
–
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer.
Similar securities
Based on sector and market capitalization
Report issue